That would be interesting to observe! However, if provided as part of the study design, women would choose between taking a pill and using a ring. Similar to what is being done under the REACH trial, 6 months on pills and 6 months on the ring followed by a crossover.
They usually need more than one efficacy trial to licence a drug.
However considering the different populations, CAB LA could be licensed for MSM and trans women, then the label updated to include cis women when the results become available.